Researchers found that people with newly diagnosed glioblastoma who received AIVITA Biomedical's AV-GBM-1, a personalized vaccine with self-renewing tumor-initiating cell-derived autologous tumor antigens, had prolonged median progression-free survival, as well as lower odds of disease progression and death after six months, compared with those in a study that created the standard of care for newly diagnosed glioblastoma. The findings, presented at the Society for Immunotherapy of Cancer's virtual annual meeting, also showed that AV-GBM-1 didn't prompt any toxicity-related treatment discontinuation.
Personalized vaccine shows promise in glioblastoma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.